Durata Therapeutics Inc (DRTX) 12.67 $DRTX
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump nearly 6% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
GlobeNewswire - Mon Mar 31, 4:10PM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence of the safety and effectiveness of its investigational drug, Dalvance (dalbavancin) for injection, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). While not bound by the guidance provided by the Committee, the FDA will consider the Committee's deliberations as part of its review of the New Drug Application (NDA) for Dalvance, which was accepted for priority review by the FDA in November 2013 with an action date of May 26, 2014.
Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Commit To Purchase Durata Therapeutics At $12.50, Earn 26.4% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:17AM CDT
Investors eyeing a purchase of Durata Therapeutics Inc stock, but cautious about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
3 Biotechs With Major Catalysts Incoming
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:45AM CDT
The end of March will be a nerve racking stretch for these three companies. Each one has nearly everything riding on a single product. And each is . Top management from Exact Sciences Corporation , Durata Therapeutics , and MannKind Corporation...
Durata Therapeutics, Inc. (DRTX) in Focus: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump 5.4% on the day.
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Durata Therapeutics reports net loss in 2013
M2 - Mon Mar 17, 9:40AM CDT
US-based pharmaceutical company Durata Therapeutics (NasdaqGM RTX) stated on Friday a net loss of USD62.1m for the year ended 31 December 2013, compared with a net loss of USD62.5m for the year ended 31 December 2012.
Morning Movers in Biotech: AstraZeneca PLC, Durata Therapeutics, Inc. and Intercept Pharmaceuticals,
George Budwell, The Motley Fool - Motley Fool - Fri Mar 14, 8:04AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Fri Mar 14, 6:03AM CDT
Durata Therapeutics, Inc. (Nasdaq RTX) today announced its fourth quarter and full year 2013 financial results.
Nasdaq stocks posting largest percentage increases
AP - Tue Apr 15, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage gainers on Nasdaq at the close of trading:
Pfizer Blockbuster Zyvox Under Attack
Cory Renauer, The Motley Fool - Motley Fool - Tue Apr 08, 8:30AM CDT
Incoming competition for Pfizer 's $1.4 billion Zyvox market is threatening on multiple fronts. With several important revenue streams drying up, this one has become more important than ever to the drug company. Recently, an FDA advisory...
What's Next for Cubist Pharmaceuticals Inc. and Durata Therapeutics, Inc.?
Amy Ho, The Motley Fool - Motley Fool - Fri Apr 04, 5:30PM CDT
Cubist Pharmaceuticals and Durata Therapeutics both won this week with nods by the FDA's advisory panels on each company's antibacterial agents. In two unanimous votes, the FDA panels agreed on the safety and efficacy of Cubist's tedizolid and...
Patient Enrollment, Acquisitions, FDA Reviews, and Results of Earnings and Clinical Trials - Analyst Notes on Arrowhead, Providence, Durata, Orthofix, and Idera
PR Newswire - Fri Apr 04, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp. (NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc. (NASDAQ: IDRA). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register
Durata Therapeutics (DRTX) in Focus: Stock Up 5.64% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Apr 02, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump nearly 6% on the day.
Nasdaq stocks posting largest volume increases
AP - Tue Apr 01, 5:03PM CDT
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
FDA Advisory Committee Unanimously Recommends Approval of Dalvance(TM) for the Treatment of Acute Bacterial Skin and Skin Structure Infections (ABSSSI)
GlobeNewswire - Mon Mar 31, 4:10PM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) announced today that the U.S. Food and Drug Administration's (FDA) Anti-Infective Drugs Advisory Committee voted 12 to 0 that the Company has provided substantial evidence of the safety and effectiveness of its investigational drug, Dalvance (dalbavancin) for injection, for the treatment of adult patients with acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA). While not bound by the guidance provided by the Committee, the FDA will consider the Committee's deliberations as part of its review of the New Drug Application (NDA) for Dalvance, which was accepted for priority review by the FDA in November 2013 with an action date of May 26, 2014. Morning Movers in Biotech: Ariad Pharmaceuticals, Exact Sciences Corporation and MannKind Corp
George Budwell, The Motley Fool - Motley Fool - Fri Mar 28, 7:59AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Commit To Purchase Durata Therapeutics At $12.50, Earn 26.4% Annualized Using Options
StockOptionsChannel.com - Tue Mar 25, 11:17AM CDT
Investors eyeing a purchase of Durata Therapeutics Inc stock, but cautious about paying the going market price of $14.41/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put...
3 Upcoming FDA Meetings You Should be Watching
Sean Williams, The Motley Fool - Motley Fool - Fri Mar 21, 1:05PM CDT
Just because we're out of earnings season doesn't mean there aren't big data-driven events happening in the health care sector. Between now and the end of the month there are three Food and Drug Administration panel meetings that are bound to...
Better Buy: Cubist Pharmaceuticals, Inc. vs. Durata Therapeutics, Inc.
George Budwell, The Motley Fool - Motley Fool - Thu Mar 20, 8:30AM CDT
Regulatory decisions are generally chaotic events for biotech companies, especially when they involve a lead clinical candidate. Approvals can send shares soaring as the market prices in future revenue, whereas a rejection nearly always results in a...
3 Biotechs With Major Catalysts Incoming
Cory Renauer, The Motley Fool - Motley Fool - Wed Mar 19, 8:45AM CDT
The end of March will be a nerve racking stretch for these three companies. Each one has nearly everything riding on a single product. And each is . Top management from Exact Sciences Corporation , Durata Therapeutics , and MannKind Corporation...
Durata Therapeutics, Inc. (DRTX) in Focus: Stock Up 5.4% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Mar 19, 7:44AM CDT
Durata Therapeutics, Inc. was a big mover last session, as the company saw its shares jump 5.4% on the day.
5 Reasons to Buy PDL BioPharma Inc
George Budwell, The Motley Fool - Motley Fool - Mon Mar 17, 1:30PM CDT
The wisdom of investing in stocks that pay dividends will never go out of style. For investors in the health care sector, however, dividends are rare, as most health care companies choose to use their cash to invest in their clinical pipelines, which...
Durata Therapeutics reports net loss in 2013
M2 - Mon Mar 17, 9:40AM CDT
US-based pharmaceutical company Durata Therapeutics (NasdaqGM
RTX) stated on Friday a net loss of USD62.1m for the year ended 31 December 2013, compared with a net loss of USD62.5m for the year ended 31 December 2012. Morning Movers in Biotech: AstraZeneca PLC, Durata Therapeutics, Inc. and Intercept Pharmaceuticals,
George Budwell, The Motley Fool - Motley Fool - Fri Mar 14, 8:04AM CDT
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis. Let's take a look at the top stories in biotech and health...
Durata Therapeutics, Inc. Reports Fourth Quarter and Full-Year 2013 Financial Results
GlobeNewswire - Fri Mar 14, 6:03AM CDT
Durata Therapeutics, Inc. (Nasdaq
RTX) today announced its fourth quarter and full year 2013 financial results. 
